Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
125.89
Nov 17 • 3:59 PM ET Dollar change-2.16 Percentage change(-1.69%)
Aftermarket Close
125.64
Aftermarket • 4:04 PM ET Dollar change-0.25 Percentage change(-0.20%)
Index
RUT
Market Cap
5.31B
Enterprise Value
4.51B
Income
-102.72M
Sales
0.00M
Book/sh
18.88
Cash/sh
18.92
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
21
IPO
Feb 04, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
6.67
P/C
6.65
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
77.68
Current Ratio
77.68
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.62
EPS next Y
-2.66
EPS next Q
-0.61
EPS this Y
19.78%
EPS next Y
2.21%
EPS next 5Y
25.50%
EPS past 3/5Y
-117.94% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-57.61%
Sales Y/Y TTM
-
EPS Q/Q
17.64%
Sales Q/Q
-
Insider Own
28.54%
Insider Trans
-14.00%
Inst Own
74.05%
Inst Trans
10.36%
ROA
-65.46%
ROE
-70.00%
ROIC
-11.74%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-8.59%
SMA50
2.13%
SMA200
30.59%
Trades
Shs Outstand
42.19M
Shs Float
30.15M
52W High
156.63 -19.63%
52W Low
32.00 293.41%
Volatility
7.02% 6.99%
ATR (14)
9.32
RSI (14)
45.82
Beta
-
Rel Volume
0.53
Avg Volume
752.43K
Volume
400,601
Perf Week
-15.19%
Perf Month
2.95%
Perf Quarter
13.18%
Perf Half Y
25.80%
Perf YTD
270.26%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
128.05
Price
125.89
Change %
-1.69%
Consensus
Strong Buy
Avg. Price Target
$187.33
Implied Upside
+48.8%
Analysts6incl. previous ratings
Rating Distribution6 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 15, 2026Initiated
RILY logoRB. Riley Securities
Buy$170+35.0%
Jun 02, 2026Initiated
NNeedham
Buy$136+8.0%
Mar 02, 2026Initiated
LLeerink Partners
Outperform$75-40.4%
Mar 02, 2026Initiated
JEF logoJJefferies
Buy$75-40.4%
Mar 02, 2026Initiated
C logoCCitigroup
Buy$85-32.5%
Mar 02, 2026Initiated
CCantor Fitzgerald
Overweight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ENRIGHT PATRICK GDirectorNov 11 '26Sale150.38500,00075,190,0001,803,474Nov 13 05:39 PM
Longitude Capital Partners V, 10% OwnerNov 11 '26Sale150.38500,00075,190,0001,803,474Nov 13 05:33 PM
Longitude Venture Partners V, 10% OwnerNov 11 '26Proposed Sale150.38250,00037,595,000Nov 12 08:43 AM
MONTANOVA CAPITAL, LLCDirectorAug 19 '26Sale107.25750,00080,437,500461,033Aug 21 06:11 PM
Averill Master Fund, Ltd.AffiliateAug 19 '26Proposed Sale107.25690,60174,066,957Aug 19 07:14 PM
Averill Madison Master Fund, LAffiliateAug 19 '26Proposed Sale107.2559,3996,370,543Aug 19 07:12 PM
Durso Timothy AugustChief Technical OfficerAug 17 '26Option Exercise12.193,45242,080121,642Aug 18 09:10 PM
Durso Timothy AugustChief Technical OfficerAug 17 '26Sale107.8243,5004,690,00578,142Aug 18 09:10 PM
Waldman Reid AlexanderChief Executive OfficerAug 17 '26Option Exercise12.193,45242,080238,324Aug 18 09:04 PM
Waldman Reid AlexanderChief Executive OfficerAug 17 '26Sale107.8667,5007,280,713170,824Aug 18 09:04 PM
Timothy DursoOfficerAug 17 '26Proposed Sale111.2887,0009,681,360Aug 17 05:39 PM
Reid Alexander WaldmanCEOAug 17 '26Proposed Sale111.28135,00015,022,800Aug 17 05:30 PM
CHILDS JOHN WDirectorAug 12 '26Sale107.12100,00010,711,700194,117Aug 14 06:01 PM
AMZL, LPShareholderAug 12 '26Proposed Sale108.95104,58711,394,754Aug 12 06:01 PM
SR One Capital Fund II AggregaShareholderAug 12 '26Proposed Sale108.95217,16223,659,800Aug 12 06:00 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorFeb 04 '26Buy37.05155,9535,778,3423,648,538Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorFeb 05 '26Buy37.9996,2003,655,079489,932Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorFeb 06 '26Buy36.3430,5211,109,056520,453Feb 09 06:28 PM
Coric VladDirectorFeb 05 '26Buy17.00117,6461,999,982319,398Feb 05 07:04 PM
CHILDS JOHN WDirectorFeb 05 '26Buy17.00294,1174,999,9892,202,006Feb 05 07:04 PM
Longitude Capital Partners V, 10% OwnerFeb 05 '26Buy17.001,075,00018,275,0002,600,399Feb 05 07:03 PM
ENRIGHT PATRICK GDirectorFeb 05 '26Buy17.001,075,00018,275,0002,600,399Feb 05 07:03 PM
Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.
CEO & DirectorDr. Reid Waldman M.D.
CFO & TreasurerMr. Dominic Carrano CPA
Chief Technical OfficerDr. Timothy Durso M.D.
General Counsel & SecretaryMr. Michael V. Greco J.D.
Chief Commercial & Strategy OfficerMr. Mark Neumann